1930 results
Keyword Nutropin Aq Remove keyword
-
List item
Veterinary medicine European public assessment report (EPAR): Halocur
halofuginone, Calves, newborn
Date of authorisation: 29/10/1999, Revision: 9, Authorised, Last updated: 23/02/2021dangerous for fish and other aquatic organisms. Any unused product … dangerous for fish and other aquatic organisms. Any unused product … dangerous for fish and other aquatic organisms. Any unused product … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2011
CHMP, Last updated: 20/05/2011somatropin-containing medicines NutropinAq, Omnitrope and Valtropin are … 20/05/2011) RoActerma: EPAR NutropinAq: EPAR Omnitrope: EPAR Valtropin … -
List item
Orphan designation: Humanised anti-IL-6 receptor monoclonal antibody (satralizumab) for: Treatment of neuromyelitis optica spectrum disorders
Date of designation: 27/06/2016, Positive, Last updated: 30/06/2021Antibodies against the protein AQP4 are found in most patients … optica spectrum disorders. AQP4 plays an important role in … production of antibodies against AQP4. By blocking IL-6, the medicine … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2011
CHMP, Last updated: 16/12/2011Corlentor: EPAR Vimpat: EPAR NutropinAq: EPAR Omnitrope: EPAR Valtropin … -
List item
Human medicine European public assessment report (EPAR): Travatan
travoprost, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 27/11/2001, Revision: 30, Authorised, Last updated: 07/06/2022drainage of the watery fluid (aqueous humour) out of the eyeball … drainage of the watery fluid (aqueous humour) out of the eyeball … -
List item
Orphan designation: paclitaxel for: Treatment of oesophagus carcinoma
Date of designation: 23/02/2011, Positive, Last updated: 04/03/2011Kingdom, for paclitaxel (aqueous gel) for the treatment of … to show that paclitaxel (aqueous gel) might be of significant … eventually die. Paclitaxel (aqueous gel) is a depot formulation … -
List item
Human medicine European public assessment report (EPAR): Izba
travoprost, Ocular Hypertension; Glaucoma, Open-Angle
Date of authorisation: 20/02/2014, Revision: 6, Authorised, Last updated: 29/11/2021drainage of the watery fluid (aqueous humour) out of the eyeball … drainage of the watery fluid (aqueous humour) out of the eyeball … -
List item
Veterinary medicine European public assessment report (EPAR): Activyl
indoxacarb, Dogs; Cats
Date of authorisation: 18/02/2011, Revision: 8, Authorised, Last updated: 05/04/2019as it may be harmful for aquatic organisms. For a full list … as it may be harmful for aquatic organisms. For a full list … -
List item
Veterinary medicine European public assessment report (EPAR): Prac-tic
pyriprole, Dogs
Date of authorisation: 18/12/2006, Revision: 10, Authorised, Last updated: 06/09/2018as it may be harmful for aquatic organisms. What are the precautions … as it may be harmful for aquatic organisms. What are the … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use,17-20 September 2007
CHMP, Last updated: 21/09/2007marketing authorisation for NutropinAq PDF icon application/pdf … Negative opinion for Nutropin AQ The CHMP adopted a negative … extension of indication for Nutropin AQ (somatropin), from Ipsen … -
List item
Human medicine European public assessment report (EPAR): Lumigan
bimatoprost, Glaucoma, Open-Angle; Ocular Hypertension
Date of authorisation: 08/03/2002, Revision: 37, Authorised, Last updated: 20/07/2022drainage of the watery fluid (aqueous humour) out of the eyeball … drainage of the watery fluid (aqueous humour) out of the eyeball … -
List item
Veterinary medicine European public assessment report (EPAR): Profender
emodepside, praziquantel, Dogs; Cats
Date of authorisation: 27/07/2005, Revision: 19, Authorised, Last updated: 25/01/2021as it may be harmful for aquatic organisms. What are the precautions … as it may be harmful for aquatic organisms. What are the … -
List item
Press release: Sanofi-aventis withdraws its marketing authorisation application forAquilda (satavaptan)
Last updated: 28/05/2008authorisation for the medicine Aquilda (satavaptan) 5 and 25 mg … 25 mg film-coated tablets. Aquilda was intended to be used for … marketing authorisation for Aquilda was submitted to the EMEA … -
List item
Orphan designation: Human engineered monoclonal antibody specific for transforming growth factor β2 for: Prevention of scarring in glaucoma filtration surgical procedures
Date of designation: 30/05/2001, Withdrawn, Last updated: 05/05/2011a new passageway by which aqueous fluid accumulated inside … filter allows the drainage of aqueous fluid from inside the anterior … the white of the eye). The aqueous fluid is eventually absorbed … -
List item
Orphan designation: 5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine for: Treatment of acute myeloid leukaemia
Date of designation: 14/09/2007, Positive, Last updated: 08/05/2014Pharma ASA changed name to Aqualis ASA. For a list of the administrative … Pharma ASA changed name to Aqualis ASA. What is acute myeloid … Sponsor’s contact details: Aqualis ASA Sjølyst Plass 2 0278 … -
List item
National expert: Jens Sonksen, European Medicines Agency (updated)
- Declaration of interests - 45.92 KB | PDF
- Curriculum Vitae - 69.77 KB | PDF
disease Past 01-08- 2017 01-09- 2018 Aquinox AQX_1125 bladder pain syndrome/interstitial … -
List item
News: New treatment for rare autoimmune disease of nerve cells
CHMP, Last updated: 23/04/2021who are positive for anti-aquaporin-4 antibodies AQP4-IgG). NMOSD is a rare and … in 119 patients who were AQP4+ and received Enspryng alone … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2010
CHMP, Last updated: 17/12/2010somatropin-containing medicines NutropinAq, Omnitrope and Valtropin are … -
List item
National expert: Tonje Høy, Norwegian Medicines Agency (updated)
- Declaration of interests - 40.42 KB | PDF
- Curriculum Vitae - 29.59 KB | PDF
different water oxygen levels. Aquaculture 1991; 95: 33 – 40. 6. Horsberg … anti_parasitic medicines in aquaculture", run by the International … anti_parasitic medicines in aquaculture" by IRIS (International Research … -
List item
Press release: Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 16-18 January 2018
CVMP, Last updated: 19/01/2018Panacur AquaSol … for Advocate and Panacur AquaSol to add new therapeutic indications … product withdrawal periods in aquatic species. The guideline … -
List item
VICH GL38 Environmental impact assessments for veterinary medicinal products - Phase II - Scientific guideline
Last updated: 01/01/2005environmental risk assessment , aquatic, terrestrial … 13 3.1.3.1 Tier A Aquatic Effects Studies...............................................................13 …
-
List item
VICH GL6 Environmental impact assessment (EIAS) for veterinary medicinal products - Phase I - Scientific guideline
Last updated: 20/07/2000Environmental risk assessment , aquatic, terrestrial, phase I tier … treat species reared in the aquatic or in the terrestrial environment? The … of species reared in the aquatic environment, proceed to Questions …
-
List item
News: Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 10-12 May 2021
CVMP, Last updated: 17/05/2021Panacur AquaSol … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): grass pollen, birch pollen
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000963-PIP01-10, Route(s) of administration: Sublingual use, Pharmaceutical form(s): Oral solution
Decision date: 22/12/2010, Last updated: 25/01/2011, Compliance check: Xgranting of a waiver for aqueous allergen extract of grass … 000963-PIP01-10 Decision aqueous allergen extract of grass … granting of a waiver for aqueous allergen extract of grass … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dermatophagoides pteronyssinus
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Pneumology-allergology
PIP number: EMEA-000960-PIP01-10, Route(s) of administration: Sublingual use, Pharmaceutical form(s): Oral solution
Decision date: 22/12/2010, Last updated: 26/01/2011, Compliance check: Xgranting of a waiver for aqueous allergen extract of dermatophagoides … granting of a waiver for aqueous allergen extract of dermatophagoides … granting of a waiver for aqueous allergen extract of dermatophagoides …